This session explores how pharma companies approach and build effective partnerships with computational drug discovery firms. Industry experts will share insights on best practices for data sharing, strategies for navigating cultural challenges with biotech and startups, and the role of explainable AI in fostering trust. The discussion will also cover common mistakes companies make when approaching pharma and the considerations around using proprietary algorithms versus open-source models to advance drug discovery.

This is an invite-only exclusive luncheon with senior leaders at the forefront of AI and BioPharma to explore how decades of progress in computational technologies can inform the next wave of breakthroughs in biology. Featuring insights from Sandy Pentland (MIT), Richard Socher (You.com, ex-Chief Scientist at Salesforce), Ola Wlodek (Constructive Bio), and Simon Kohl (Latent Labs) this conversation will examine the strategic parallels between past inflection points in computing and today’s rapidly evolving AI-driven biological revolution. From data infrastructure to predictive modeling and decision-making under uncertainty, what can we learn—and what must we do differently—as we chart the future of biology.